Vivus ( VVUS) Drug/indication: Qnexa for obesity Approval decision date: July 17 A February FDA advisory panel voted 20-2 to support Qnexa's approval. FDA's decision was delayed by three months to allow the company and regulators to finalize a risk-management plan. Amarin ( AMRN) Drug/indication: AMR101 for treatment of patients with very high triglycerides Approval decision date: July 26 Horizon Pharma ( HZNP) Drug/indication: Lodotra for rheumatoid arthritis Approval decision date: July 26 Progenics ( PGNX) and Salix Pharmaceuticals ( SLXP) Drug/indication: Relistor SC for opioid-induced constipation Approval decision date: July 27 Regeneron Pharmaceuticals and Sanofi ( SNY) Drug/indication: Zaltrap for colon cancer Approval decision date: Aug. 4 Zaltrap has posted mixed results in phase III clinical trials. Ironwood Pharmaceuticals ( IRWD) Drug/indication: Linaclotide for chronic idiopathic constipation and irritable bowel syndrome Approval decision date: Sept. 8 Navidea Biopharmaceuticals ( NAVB) Drug/indication: Lymphoseek, a radioactive tracing agent for lymph node mapping Approval decision date: Sept. 10 Regeneron Pharmaceuticals Drug/indication: Eylea for retinal vein occlusion Approval decision date: Sept. 21 This is an expanded approval for Eylea, already approved for macular degeneration. NPS Pharmaceuticals ( NPSP) Drug/indication: Gattex for short bowel syndrome Approval decision date: Sept. 28 Sanofi and Isis Pharmaceuticals ( ISIS) Drug/indication: Kynamro for hypercholesterolemia Approval decision date: Sept. 28 Raptor Pharmaceutical ( RPTP) Drug/indication: RP103 for cystinosis Approval decision date: Oct. 1 Celgene Drug/indication: Abraxane for non-small cell lung cancer Approval decision date: Oct. 12 Abraxane is already approved for the treatment of breast cancer. Santarus ( SNTS) Drug/indication: Uceris for ulcerative colitis Approval decision date: Oct. 16 Impax Labs ( IPAX) Drug/indication: IPX066 for Parkinson's disease Approval decision date: Oct. 19 Dynavax ( DVAX) Drug/indication: Heplisav for hepatitis B prevention Approval decision date: Oct. 26 United Therapeutics ( UTHR) Drug/indication: Oral Remodulin for pulmonary arterial hypertension Approval decision date: Oct. 26 Cornerstone Therapeutics ( CRTX) Drug/indication: Lixivaptan for hyponatremia Approval decision date: Oct. 29 Celgene Drug/indication: pomalidomide for refractory/relapsed multiple myeloma Approval decision date: Fourth quarter Celgene announced submission of the pomalidomide filing during the second quarter. Biogen Idec ( BIIB) Drug/indication: BG-12 for multiple sclerosis Approval decision date: Dec. 28 BG-12 would be Biogen's first pill for multiple sclerosis. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.